WEBINAR RECORDING AVAILABLE - WATCH ON DEMAND

Data’s influence early in the commercialization process

Are you getting the most out of your data and analytics? Is it where you begin and not where you end? From naming and branding considerations to access hurdles, commercialization success lies in an integrated approach to data and analytics before Day 1.

In this webinar you will hear from experts on:
  • How to successfully tap into analytics as early as possible to guide each step of the commercialization process
  • The importance of data and analytics as you’re building your brand
  • The influence data and analytics can have when it comes to access challenges
watch now
Watch the webinar on demand
Rommel Fernandez

Rommel Fernandez

Chief Analytics Officer, Fingerpaint

Rommel Fernandez is a strategic and thoughtful leader who has a deep understanding of commercialization in the biotech and pharmaceutical space. He began his career in consulting at Inforte working in multiple industry verticals from start-ups to Fortune 500 companies. Rommel has more than 15 years of experience in the biotech and pharmaceutical industry with launch experience for first-in-class diabetes brands and treatment for distributive shock in the intensive care unit space. Rommel has held a variety of leadership roles that span multiple areas, including building commercial organizations from the ground up and developing new commercial models. He specializes in analytics and has a passion for using data and insights to help deliver the right product to the right patient. As chief analytics officer at Fingerpaint, he not only drives the data-centric culture, but also helps develop performance-driven campaigns that address the challenges biopharma faces. Prior to joining the Fingerpaint leadership team, he was vice president at 1798 Consulting, a Fingerpaint company. Rommel graduated from San Diego State University with a Bachelor of Science in business administration—information decision systems.

Roshawn Blunt

Roshawn Blunt

Managing Director, 1798, a Fingerpaint company

Roshawn Blunt is a highly respected biotech consultant who has had extensive success cultivating industry partnerships, influencing stakeholders, and delivering positive results. She began her pharmaceutical career at Boston Consulting Group before transitioning out of consulting and into positions on the manufacturer and provider sides, such as her role as a health policy director in Washington, DC, at Amgen, followed by being the global director of health economics at Johnson & Johnson. She also worked in healthcare as the head of strategy, marketing, and communications for Long Beach Memorial Medical Center and Miller Children’s Hospital. Roshawn returned to consulting as the managing director at the Aequitas Group. She founded 1798, where her leadership has helped multiple companies achieve first-in-industry market access milestones. 1798 was acquired by Fingerpaint in 2020. Roshawn earned a bachelor’s degree in international and public affairs at Princeton University and an MBA with a concentration in marketing and biotechnology at Northwestern University Kellogg School of Management.

Brannon Cashion

Brannon Cashion

Managing Partner, Leaderboard Branding, a Fingerpaint company

With over 25 years of life sciences and healthcare naming and branding experience, Brannon has spent his career growing partnerships and guiding companies to brand success. Brannon is a founding partner of Leaderboard Branding and has built a best-in-class branding consultancy with a team of experts that works to develop creative and strategic solutions that exceed client expectations. As a leader in the branding and naming industry, he has worked on over 1000 client engagements, served as a keynote speaker and guest lecturer, and is often quoted as an expert on all things branding. Brannon is a graduate of the University of North Carolina at Chapel Hill.

Arsalan Arif
moderator

Arsalan Arif

Founder & publisher, endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.